Successful treatment of a patient with both systemic lupus erythematosus and progressive hepatitis C using immunosuppressive therapy and interferon beta

Sirs,

Systemic lupus erythematosus (SLE) is characterized by loss of tolerance to nuclear antigens and inflammation in multiple organs. SLE patients could also have pulmonary arterial hypertension (PAH). One of the most prominent features of SLE is continuous activation of the type I interferon (IFN) signature (1). This leads us to presume that the administration of type I IFN to SLE patients should be avoided because it can exacerbate SLE. Here we report a patient with both SLE and progressive hepatitis C virus (HCV) infection treated successfully using prednisolone (PSL), cyclophosphamide, IFNβ and ribavirin.

A 28-year-old woman developed excessive bruising due to low platelet count. She had no medical history. She was diagnosed as having idiopathic thrombocytopenic purpura and treated with PSL (unknown dose) and splenectomy at another hospital. Her platelet count was maintained with PSL 5 mg/day. She developed dyspnea and arthralgia at the age of 34 and visited our hospital. Detailed examination showed low platelet count (147,000/μl), high urine protein level (1.15g/day), pericarditis, positive antinuclear antibody (spec Fritz×1280), high dsDNA level (72.7IU/ml), and low C3 level (62.5mg/dl). Other autoantibodies were negative. Based on these findings, she was diagnosed as having SLE. Right heart catheterization revealed PAH, with mean pulmonary arterial pressure (mPAP) of 58mmHg. In the course of successful treatment for SLE-PAH with PSL 40 mg/day, she achieved remission from SLE-PAH. We therefore report a patient with both SLE and progressive hepatitis C virus (HCV) infection treated successfully using prednisolone (PSL), cyclophosphamide, IFNβ and ribavirin.

We avoided polyethylene glycol (PEG)-IFNα because a shorter half-life of IFN would be better, and IFNα required PEG attachment. After treatment, both her SLE and HCV infection were resolved. Previous reports showed that treatment with IFNα (2) and IFNβ (3, 4) can lead to drug-induced lupus, and IFNβ can lead to drug-induced pulmonary hypertension (5). These findings indicate administration of not only IFNα, but IFNβ, can exacerbate SLE-PAH. While it has also been reported that 8 SLE patients with HCV reactivation treated with pegylated IFN plus ribavirin did not show exacerbation of SLE (6). The clinical outcome of our case suggested that IFNβ administration does not exacerbate SLE. There exists another possibility that enhanced immunosuppressant drugs partly prevented IFNβ from exacerbating SLE; however, we supposed that ribavirin did not suppress the flare of SLE because ribavirin, having anti-HCV activity, is thought to activate the immune system.

IFNβ would be the treatment of choice for SLE patients who have HCV and cannot use IFN-free therapy due to adverse effects of direct-acting antivirals. In addition, SLE patients with malignant melanoma or glioblastoma may benefit from IFNβ administration. When using IFNβ in patients with SLE or pulmonary hypertension, we need to monitor for exacerbation cautiously. Future studies should address the similarities and differences between IFNβ and IFNγ regarding the aetiology of SLE.

Y. SUGIMORI
H. YAMASHITA
H. YORIFUJI
Y. TAKAHASHI
H. KANEKO
A. MIMORI

Division of Rheumatic Diseases, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.

Please address correspondence and reprint requests to:
Dr Hirotsuki Yamasita,
Division of Rheumatic Diseases,
National Center for Global Health and Medicine,
1-21-1 Toyama,
Shinjuku, Tokyo 162-8655, Japan.
E-mail: hirotsuki_yjg2005@yahoo.co.jp

Funding: this work was supported in part by Grants-in-Aid for Research from the National Center for Global Health and Medicine (29-2001).

Competing interests: none declared.

© Copyright CLINICAL AND EXPERIMENTAL RHUMATOLOGY 2018.

References